ADVERTISEMENT
Use of a 12-Gene DCIS Score to Guide Radiotherapy Decisions for Patients With Ductal Carcinoma in Situ
Featuring Seema Khan, MD
Seema Khan, MD, Northwestern University School of Medicine, Chicago, Illinois, discussed 5-year clinical outcomes from E4112 which identified that >90% of patients who underwent a 12-gene DCIS score to predict radiotherapy benefit followed DS-based recommendations.
These results were first presented at the 2023 San Antonio Breast Cancer Symposium.
Source:
Khan S, Romanoff J, Gastonis C, et al. Magnetic resonance imaging and a 12-gene expression assay to optimize local therapy for ductal carcinoma in situ: 5-year clinical outcomes of E4112. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, Texas. Abstract GS03-01
© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement